Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topoteсan on in vivo tumor models

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	581-593
Number of pages	13
Journal	European Journal of Medicinal Chemistry
Volume	161
DOIs	https://doi.org/10.1016/j.ejmech.2018.10.055
Publication status	Published - 1 Jan 2019

Campthotecin, Lewis lung carcinoma, Molecular modelling, Topotecan, Tyrosyl-DNA phosphodiesterase 1 (Tdp1), Usnic acid, STRAND BREAK REPAIR, HUMAN-CELLS, EMPIRICAL SCORING FUNCTIONS, TOPOISOMERASE-I, IDENTIFICATION, CAMPTOTHECIN, PROTEIN-LIGAND DOCKING, TDP1, BIOLOGICAL EVALUATION, USNIC ACID, Humans, Structure-Activity Relationship, Topotecan/chemical synthesis, Dose-Response Relationship, Drug, Quantum Theory, Neoplasms, Experimental/drug therapy, Lung Neoplasms/drug therapy, Molecular Structure, Cell Proliferation/drug effects, Mice, Inbred C57BL, Models, Molecular, Topoisomerase I Inhibitors/chemical synthesis, Antineoplastic Agents/chemical synthesis, Phosphoric Diester Hydrolases/metabolism, Animals, Cell Line, Tumor, Mice, Drug Screening Assays, Antitumor

ID: 17302962